Gen QA

MEMBER LOGIN

MENU menu

Close close menu

Central Nervous System (CNS) tumours

BACK TO EQA DIRECTORY

Testing for 1p/19q co-deletion status and/or MGMT promotor methylation and/or IDH1/IDH2 status in CNS tumours.

EQA INFORMATION

EQA Code
TCNS
Submission
Clinical Report
Techniques
Any methodology
Eligibility
All laboratories worldwide
Language
English, French, German, Italian, Polish, Portuguese, Spanish
EQA Accreditation
EQA accredited to ISO 17043:2010
EQA open

13 January 2025

19 January 2026

Testing period
6 weeks

OTHER INFORMATION

 What are participants required to do?
  • Enrolled participants will receive details by email when an EQA is open for assessment and/or samples have been dispatched.  
  • Participants are expected to access the instructions and information for the cases/samples online and to analyse them according to their laboratory/centre protocols. 
  • Participants must submit their anonymised results by the deadline using their standard laboratory report or a proforma provided by GenQA.  The submitted results are independently assessed for the accuracy of the analytical/genotyping results, clinical interpretation of the results (if appropriate) and clerical accuracy (including report layout and content). 

What can I expect as a participant?
Every participant will receive:
  • An Individual Laboratory/Centre Report (ILR/ICR) with educational advice for each distribution of this EQA.
  • The Summary report for each distribution of this EQA which contains information regarding general findings, a summary of methodologies used, common errors, number of participants and benchmarking. 
  • Access to a live Performance Certificate summarising your performance status for all EQAs in which you are enrolled.

Please note: EQA details may be subject to change prior to EQA distribution.  

PRODUCTS

Sample type: FFPE (Formalin Fixed Paraffin Embedded sections)
Testing/analysis:
  • IDH1 / IDH2 status
  • 1p/19q co-deletion status
  • MGMT promoter methylation
Testing of all genes for this EQA is not compulsory.  Please test and report only the genes included in your routine laboratory scope.   
Conditions/Gene target(s):
CNS Tumours including: 
  • Oligodendroglioma
  • Astrocytoma
  • Glioblastoma
  • Glioma 
Number of cases: Up to four

PURCHASE NOW

 

ASK A QUESTION

Central Nervous System (CNS) tumours

Enter your details here: